KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 90 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.31 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $45,766 | -6.3% | 34,154 | +172.1% | 0.00% | – |
Q1 2023 | $48,831 | -72.5% | 12,553 | -76.0% | 0.00% | -100.0% |
Q4 2022 | $177,762 | -77.8% | 52,283 | -57.9% | 0.00% | -50.0% |
Q4 2021 | $799,000 | +125.1% | 124,274 | +261.2% | 0.00% | +100.0% |
Q2 2021 | $355,000 | -71.3% | 34,409 | -57.0% | 0.00% | -88.9% |
Q4 2020 | $1,239,000 | -46.5% | 80,053 | -49.5% | 0.01% | -71.0% |
Q3 2020 | $2,314,000 | +195.5% | 158,523 | +283.4% | 0.03% | +138.5% |
Q2 2020 | $783,000 | -28.8% | 41,350 | -27.8% | 0.01% | -53.6% |
Q1 2020 | $1,100,000 | +145.5% | 57,245 | +144.9% | 0.03% | +833.3% |
Q4 2019 | $448,000 | +282.9% | 23,378 | +19.5% | 0.00% | +200.0% |
Q2 2019 | $117,000 | -76.4% | 19,558 | -63.0% | 0.00% | -83.3% |
Q4 2018 | $495,000 | -44.2% | 52,817 | +1.4% | 0.01% | -45.5% |
Q3 2018 | $887,000 | +254.8% | 52,100 | +254.4% | 0.01% | +266.7% |
Q2 2018 | $250,000 | +101.6% | 14,700 | +14.0% | 0.00% | +50.0% |
Q4 2017 | $124,000 | -23.0% | 12,897 | -24.6% | 0.00% | -71.4% |
Q4 2016 | $161,000 | – | 17,100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 4,767,078 | $80,993,000 | 5.22% |
Palo Alto Investors LP | 4,663,324 | $79,230,000 | 3.17% |
DOHENY ASSET MANAGEMENT /CA | 282,945 | $4,807,000 | 2.61% |
Private Capital Advisors, Inc. | 416,900 | $7,083,000 | 2.22% |
Sandia Holdings, LLC | 119,739 | $2,034,000 | 0.91% |
Virtus ETF Advisers LLC | 44,986 | $764,000 | 0.68% |
Birchview Capital, LP | 50,000 | $850,000 | 0.58% |
Schonfeld Strategic Advisors LLC | 415,600 | $7,061,000 | 0.38% |
EMERALD ADVISERS, LLC | 561,317 | $9,537,000 | 0.36% |
Kazazian Asset Management, LLC | 20,672 | $351,000 | 0.32% |